Vectura Share Discussion Threads

[rivaldo] 29/7/2016 08:28

Numis reiterate their Buy and 246p target:

[beckaroo] 29/7/2016 08:10

When I searched for the patent in the RNS, I found it was filed in 2010 and published in 2012, hence not included in original agreement

[boadicea] 28/7/2016 22:02

I would not expect it to be the case but it may be worth noting the following possible explanation appearing under "Term of Patent in the United States" in Wikipedia -

"Design patents have a shorter term than utility patents.... Design patents filed prior to May 13, 2015 have a term of 14 years from issuance."

Note not just the shorter term but the replacement of "filing" by "issuance".

[hashertu] 28/7/2016 18:07

If I search for the patent number referenced in the RNS, Google tells me that it has a priority (filing) date in 2000. Patent protection should last for 20 years from that date.
So,I too am confused about the basis of litigation.
What might make more sense is if "A number of these patents expire ..." should read "A number of these licences expire ...".

[carpadium] 28/7/2016 16:38

Much better day than I thought likely. Here's to an amicable settlement between the two without recourse to law, we know there's only ever one winner in such matters.
Wouldn't surprise to see VEC release a positive news release pretty soon, something to encourage investors to continue their support.

Richtea 27K, snap!

[jscowi] 28/7/2016 14:25

Rjd1233 - I have used Barclays for many a year never had a problem. They provide trailing stops, basic stops etc

[sikhthetech] 28/7/2016 14:09

Being ex-skp holder, I really believed things might improve after the merger and the roller coaster ride may be a thing of the past... it hasn't been so far...

[rjd1233] 28/7/2016 13:36

Jscowi may I ask which broker you use and whether they offer trailing stop losses? TD DIrect who I use don't and looking for a Broker who does? apologies as off topic.

[jscowi] 28/7/2016 12:27

Likewise I was stopped out this morning after holding for many a year.

Has gone sideways for too long now, better shares out their plus cannot let that profit disappear.

Will keep an eye on VEC which has served me well, now time to move on.

[luffness] 28/7/2016 12:11

Way I read it GSK have declined to start paying a licence to use additional Vec patents but will be using them anyway (or at least Vec are alleging this)

the key seems to be "Vectura has now issued proceedings in the US to enforce its patents relating to these products"

[richtea1701] 28/7/2016 11:55

Thanks Popper - that makes a lot of sense

[popper joe] 28/7/2016 11:38

Richtea, thanks for the reply. I realise that we are trying to assess this with much of the information missing, but it is not GSK's role to renew patents. The role of GSK's board is to do the best for GSK's shareholders. If the patents on the technologies that they employ with their drugs have expired then their shareholders would not expect them to keep paying for their continued use. I can only think that VEC's stance is that if GSK continue to use the VEC technologies even though the patents have expired then they need to continue to pay a licence fee. I suppose that would require GSK to reformulate to create generic versions. But that would take time, so they must think that they don't need to licence non-patented technology. I tend to agree with that!

[rjd1233] 28/7/2016 11:18

Been an up and down ride with VEC since June and was stopped out first thing am with small profit. Will see what happens in the next week or so as to getting back in or not.

[soundbuy] 28/7/2016 11:15

So, GSK not about to launch a bid for VEC then :)

[richtea1701] 28/7/2016 11:01

Maybe it is strong diesel? Market seems tolerant

[diesel] 28/7/2016 10:43

Popper, there does need to be some clarity, it does not bode well for future collaborations to start legal proceedings unless the case is strong and the compensation significant.

[9degrees] 28/7/2016 10:40

I think that VEC management need to put out a bit more info to inform investors. This very "loose" news

[richtea1701] 28/7/2016 10:34

Popper - I am not sure but the language used implies that Vec expected them to extend their licence/patent. Have they breached contract by not adhering to terms and agreements. In prior statement Vec implied that they had material indication that patents would be renewed? I'm no expert.

[popper joe] 28/7/2016 10:27

Could someone please explain in simple terms what this spat is about? I read that VEC had patents on certain technologies that expired in July 2016 and that GSK had licensed the use of those technologies. If the patents have now expired, why should VEC expect GSK to continue to pay a licence fee? What is meant by the sentence: "GSK does not wish to exercise the option to take a license to any additional patents under the patent licence and option agreement"? If the patents have expired what additional patents might this refer to? Sorry if these questions seem a bit naive, am I missing the obvious?

[soundbuy] 28/7/2016 08:53

Early days but reckon this was already in the price given the erosion in the share price here...........

[scotches] 28/7/2016 08:52

Having already endured 16 years of SKP and VEC in various forms the GSK news is but a minor scratch.

Like others have mentioned what exactly is the VEC case for a legal infringement. Are they indicating that continued sales of the products mentioned will be using VEC tech and therefore a fee should apply. Since the break clause is only triggered on July 31 the infringements have not happened yet.

The price action on VEC post brexit was strange. All other pharmas shot up as the benefits of revenue in non Sterling denominations was tallied into earnings projections. Just shows how a bit of insider knowledge can assist your trading.

[diesel] 28/7/2016 08:48

Thought the reaction might have been more severe, but I guess the inst's suspected this was coming, and some reassurance was given on earnings outlook.

[soundbuy] 28/7/2016 08:22

VEC Peel Hunt Buy 150.15 150.00 200.00 200.00 Reiterates

[soundbuy] 28/7/2016 08:18

VEC JP Morgan Cazenove Overweight 150.15 150.00 230.00 230.00 Retains